C
Clare Cruickshank
Researcher at Institute of Cancer Research
Publications - 29
Citations - 1608
Clare Cruickshank is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 9, co-authored 21 publications receiving 1084 citations. Previous affiliations of Clare Cruickshank include University of London.
Papers
More filters
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
TL;DR: Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer after 5 years follow-up.
Journal ArticleDOI
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Douglas Brand,Douglas Brand,Alison Tree,Alison Tree,Peter Ostler,Hans van der Voet,Andrew Loblaw,William Chu,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,Daniel Henderson,Stephanie Brown,Clare Cruickshank,Stephanie Burnett,A. Duffton,Clare Griffin,Victoria Hinder,Kirsty Morrison,Kirsty Morrison,O. Naismith,Emma Hall,Nicholas van As,Nicholas van As,D Dodds,E Lartigau,S Patton,Alan J. Thompson,Mathias Winkler,P Wells,T Lymberiou,Daniel Saunders,M Vilarino-Varela,P Vavassis,Theodoros Tsakiridis,R Carlson,George Rodrigues,Jacob Tanguay,S Iqbal,Scott C. Morgan,A Mihai,A Li,O Din,Miguel Panades,R Wade,Yvonne Rimmer,J Armstrong,N Oommen +54 more
TL;DR: The results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity.
Journal ArticleDOI
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Anna Wilkins,Helen Mossop,Isabel Syndikus,Vincent Khoo,D. Bloomfield,Chris Parker,John P Logue,Christopher D Scrase,Helen Patterson,Alison Birtle,John Staffurth,Zafar Malik,Miguel Panades,C. Eswar,John Graham,Martin J. Russell,Peter Kirkbride,Joe M. O'Sullivan,Annie Gao,Clare Cruickshank,Clare Griffin,David P. Dearnaley,Emma Hall +22 more
TL;DR: The incidence of patient-reported bowel symptoms was low and similar between patients in the 74 Gy control group and the hypofractionated groups up to 24 months after radiotherapy, and comparisons between fractionation groups were done at 24 months post-radiotherapy.
Journal ArticleDOI
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)
S. Nicholson,Emma Hall,S. J. Harland,John D. Chester,John D. Chester,Lisa Pickering,Jim Barber,Tony Elliott,Alastair Thomson,Stephanie Burnett,Clare Cruickshank,Bernadette M Carrington,Rachel Waters,Amit Bahl +13 more
TL;DR: The results do not support the routine use of TPF, but the observed complete responses support further investigation of combination chemotherapy in the neoadjuvant setting.
Journal ArticleDOI
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial
James M. Wilson,David P. Dearnaley,Isabel Syndikus,Vincent Khoo,Alison Birtle,D. Bloomfield,Ananya Choudhury,John Graham,C.L. Ferguson,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Yvonne Rimmer,Christopher D Scrase,John Staffurth,Andrew Stockdale,Clare Cruickshank,Clare Griffin,Emma Hall,CHHiP Investigators +21 more
TL;DR: Hypofractionated radiation therapy appears to be well tolerated and effective in men aged ≥ 75 years, and the 57-Gy schedule has potential advantages in that it may moderate long-term side effects without compromising treatment efficacy in this group.